aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
Globe Newswire•13/10/2026•08:00 ET
0
Key Highlights
- ➤ATYR0101 publication demonstrates anti-fibrotic effects in lung fibrosis models
- ➤ATYR0101 reduced collagen content and Ashcroft score versus nintedanib control
- ➤ATYR0101 is undergoing IND-enabling studies and expected to enter the clinic in 2027
- ➤ATYR0101 targets LTBP-1 to induce myofibroblast apoptosis
- ➤ATYR0101 demonstrated anti-fibrotic effects in lung and kidney fibrosis models
Expert Statements
Leslie A. Nangle, Vice President, Research at aTyr Pharma
“Fibrosis remains a major global health challenge across multiple organ and tissue systems with limited therapies that only slow disease progression.”
Leslie A. Nangle, Vice President, Research at aTyr Pharma
“This publication highlights the novel mechanism by which ATYR0101 disrupts fibrosis through a unique molecular program that facilitates a transition towards a restorative phenotype thus fundamentally altering the underlying fibrotic cellular landscape.”
Leslie A. Nangle, Vice President, Research at aTyr Pharma
“These findings suggest that ATYR0101 does not merely stop disease progression but may also facilitate a reversal of fibrotic pathology, providing a differentiated approach to current anti-fibrotic therapies in conditions such as idiopathic pulmonary fibrosis, where more effective treatment options are greatly needed.”
Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis.
ATYR0101 is currently undergoing IND-enabling studies and expects to be advanced into the clinic in 2027.
Get started
Create a free account to read the full story.